Tarasaponin VIICAS# 144118-18-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 144118-18-3 | SDF | Download SDF |
PubChem ID | 3083391 | Appearance | Powder |
Formula | C52H84O21 | M.Wt | 1045.22 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (4aS,6aR,6aS,6bR,10S,12aR,14bR)-10-[(2S,3R,4S,5S)-5-hydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate | ||
SMILES | CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(CO6)O)OC7C(C(C(C(O7)CO)O)O)O)OC8C(C(C(CO8)O)O)O)C)C)C2C1)C)C(=O)OC9C(C(C(C(O9)CO)O)O)O)C | ||
Standard InChIKey | MLIQJRVPWRKGIO-BIRDKCKZSA-N | ||
Standard InChI | InChI=1S/C52H84O21/c1-47(2)14-16-52(46(65)73-44-39(64)36(61)34(59)28(20-54)69-44)17-15-50(6)23(24(52)18-47)8-9-30-49(5)12-11-31(48(3,4)29(49)10-13-51(30,50)7)70-45-41(72-42-37(62)32(57)25(55)21-66-42)40(26(56)22-67-45)71-43-38(63)35(60)33(58)27(19-53)68-43/h8,24-45,53-64H,9-22H2,1-7H3/t24-,25-,26+,27-,28-,29?,30-,31+,32+,33-,34-,35+,36+,37-,38-,39-,40+,41-,42+,43-,44+,45+,49+,50-,51-,52+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Tarasaponin VII Dilution Calculator
Tarasaponin VII Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 0.9567 mL | 4.7837 mL | 9.5674 mL | 19.1347 mL | 23.9184 mL |
5 mM | 0.1913 mL | 0.9567 mL | 1.9135 mL | 3.8269 mL | 4.7837 mL |
10 mM | 0.0957 mL | 0.4784 mL | 0.9567 mL | 1.9135 mL | 2.3918 mL |
50 mM | 0.0191 mL | 0.0957 mL | 0.1913 mL | 0.3827 mL | 0.4784 mL |
100 mM | 0.0096 mL | 0.0478 mL | 0.0957 mL | 0.1913 mL | 0.2392 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Deltarasin hydrochloride
Catalog No.:BCC4270
CAS No.:1440898-82-7
- Deltarasin
Catalog No.:BCC1524
CAS No.:1440898-61-2
- Febuxostat
Catalog No.:BCC2556
CAS No.:144060-53-7
- 6-O-Syringoylajugol
Catalog No.:BCN6246
CAS No.:144049-72-9
- Piclamilast
Catalog No.:BCC6215
CAS No.:144035-83-6
- BRD73954
Catalog No.:BCC5652
CAS No.:1440209-96-0
- Sodium Nitroprusside
Catalog No.:BCC4844
CAS No.:14402-89-2
- Sulfapyridine
Catalog No.:BCC4729
CAS No.:144-83-2
- Sulfamethizole
Catalog No.:BCC4856
CAS No.:144-82-1
- Sulfathiazole sodium
Catalog No.:BCC5207
CAS No.:144-74-1
- Zeaxanthin
Catalog No.:BCN2380
CAS No.:144-68-3
- Oxalic acid
Catalog No.:BCN8515
CAS No.:144-62-7
- Fmoc-Asp-OAll
Catalog No.:BCC3086
CAS No.:144120-53-6
- Fmoc-Glu-OAll
Catalog No.:BCC3490
CAS No.:144120-54-7
- Eprosartan Mesylate
Catalog No.:BCC4658
CAS No.:144143-96-4
- Ledipasvir acetone
Catalog No.:BCC4046
CAS No.:1441674-54-9
- Indoxacarb
Catalog No.:BCN2263
CAS No.:144171-61-9
- 1-Acetyl-4-methylpiperazine hydrochloride
Catalog No.:BCC6615
CAS No.:144205-68-5
- YYA-021
Catalog No.:BCC5346
CAS No.:144217-65-2
- Dehydroadynerigenin glucosyldigitaloside
Catalog No.:BCN1568
CAS No.:144223-70-1
- ML 337
Catalog No.:BCC6345
CAS No.:1443118-44-2
- 1-Deazaadenosine
Catalog No.:BCC6204
CAS No.:14432-09-8
- Trilepisflavan
Catalog No.:BCN6786
CAS No.:1443218-16-3
- YM 26734
Catalog No.:BCC7396
CAS No.:144337-18-8
Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study.[Pubmed:28369332]
Eur Heart J Cardiovasc Imaging. 2018 Mar 1;19(3):329-338.
Aims: To show non-inferiority of the 67- or 87 microm thick, sirolimus-eluting Orsiro drug eluting stent (DES) to the 122 microm thick, biolimus-eluting Nobori DES regarding size of vessel lumen outside the stent at 13-month follow-up. Methods and results: This study was a substudy to the SORT-OUT VII trial, a prospective, 1:1-randomized, comparison of the two stents in patients with stable coronary artery disease or acute coronary syndrome. Optical coherence tomography was acquired after percutaneous coronary intervention and at 13-month follow-up. The substudy was powered to access non-inferiority (Delta = 0.60 mm2) of the Orsiro DES to the Nobori DES for the primary endpoint of mean extra stent lumen (ESL) i.e. vessel lumen outside the stent at 13-month follow-up. We randomized 124 patients to Orsiro (n = 60) or Nobori (n = 64). Due to a difference in the one-sided 95%-confidence interval of 0.26 mm2, but increased to 0.82 mm2 after appropriate log-transformation, it could not be rejected that Orsiro exceeded the non-inferiority limit. Testing for superiority, Orsiro had a significantly larger mean ESL at follow-up (Orsiro: 0.11 mm2 [0.02;0.30] mm2, Nobori: 0.03 mm2 [0.00;0.17] mm2, P = 0.04). Stent strut coverage was, Orsiro: 97.6 % [93.8;99.4]%, and Nobori: 96.3 % [90.5;98,6]% (P = 0.13). Conclusion: Orsiro DES had a significantly larger mean ESL at follow-up and it could not be excluded that Orsiro exceeded the limit for non-inferiority. Nobori DES had a more heterogeneous distribution of neointima but stent strut coverage did not differ significantly between the two stents.
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.[Pubmed:28350321]
J Clin Med. 2017 Mar 28;6(4). pii: jcm6040038.
Factor VII deficiency is the most common among rare inherited autosomal recessive bleeding disorders, and is a chameleon disease due to the lack of a direct correlation between plasma levels of coagulation Factor VII and bleeding manifestations. Clinical phenotypes range from asymptomatic condition-even in homozygous subjects-to severe life-threatening bleedings (central nervous system, gastrointestinal bleeding). Prediction of bleeding risk is thus based on multiple parameters that challenge disease management. Spontaneous or surgical bleedings require accurate treatment schedules, and patients at high risk of severe hemorrhages may need prophylaxis from childhood onwards. The aim of the current review is to depict an updated summary of clinical phenotype, laboratory diagnosis, and treatment of inherited Factor VII deficiency.
Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis.[Pubmed:28383542]
Genet Med. 2017 Sep;19(9):983-988.
PURPOSE: The main purpose of the study was to provide quantitative data regarding survival and diagnostic delay. Mucopolysaccharidosis (MPS) type VII (OMIM 253220) is a progressive neurometabolic disorder caused by deficiency of the lysosomal enzyme beta-glucuronidase (GUS). Hard clinical end points have not been quantitatedMethods:We quantitatively analyzed published cases with MPS VII (N = 53/88 with sufficient data). Main outcome measures were onset of disease and survival. The role of biomarkers such as GUS residual enzyme activity and levels of storage material assessed as urinary excretion of glucosaminoglycans (GAG) as potential predictors of clinical outcomes were investigated. The analysis was conducted according to STROBE criteria. RESULTS: Median survival of the postnatally diagnosed population was up to 360 months . Median age of disease onset was the first day of life; median age at diagnosis was 11 months. Hydrops fetalis was frequent. Patients with residual GUS activity in fibroblasts more than 1.4% or urinary GAG excretion less than 602% of normal survived longer than patients with GUS enzyme activity below or GAG excretion above these thresholds. CONCLUSION: MPS VII has its disease onset prenatally. In the absence of a prenatal diagnosis, most cases are clinically apparent at birth. Our data corroborate a phenotype-biomarker association in MPS VII. The survival data characterize the natural history with important implications for therapeutic studies.Genet Med advance online publication 06 April 2017.